Back to Search
Start Over
Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
- Publication Year :
- 2020
- Publisher :
- Elsevier, 2020.
-
Abstract
- ESMO Asia Virtual Congress -- NOV 20-22, 2020 -- ELECTR NETWORK [No Abstract Available] European Soc Med Oncol AstraZenecaAstraZeneca AstraZeneca.
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.od.....10033..1c444e67685e4bd84111711263b00d14
- Full Text :
- https://doi.org/10.1016/j.annonc.2020.10.373